NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT00483561 2023-09-13
Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy
University of Nebraska
Phase 2 Terminated
NCT00025116 2020-04-06
ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
Canadian Cancer Trials Group
Phase 2 Completed
NCT00085566 2016-01-20
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00265070 2013-02-05
Trial of Iressa in Prostate Cancer Patients
AstraZeneca
Phase 2 Completed
NCT00242918 2012-02-07
Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer
Benaroya Research Institute
Phase 2 Completed
NCT00241475 2009-04-23
Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy
AstraZeneca
Phase 2 Completed
NCT00635856 2009-04-23
Open Label Trial to Assess Iressa in Prostate Cancer Patients
AstraZeneca
Phase 2 Completed